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Abstract 
Background: Although T2DM patients with COVID-19 develop a more severe 
condition compared to those without diabetes, the mechanisms for this are unknown. 
Moreover, the impact of treatment with anti-hyperglycemic drugs and glucocorticoids 
is unclear. 
Methods: From 1584 COVID-19 patients, 364 severe/critical COVID-19 patients with 
clinical outcome were enrolled for the final analysis and patients without pre-existing 
T2DM but elevated glucose levels were excluded. Epidemiological data were obtained 
and clinical-status evaluation carried out to assess the impact of T2DM and its 
management on clinical outcomes. 
Results: Of 364 enrolled severe COVID-19 inpatients, 114 (31.3%) cases had a 
history of T2DM. 27(23.7%) cases died in T2DM patients, who had more severe 
inflammation, coagulation activation, myocardia injury, hepatic injury, and kidney 
injury, compared with non-DM patients. In severe COVID-19 patients with 
T2DM, we demonstrate a higher risk of all-cause fatality with glucocorticoid treatment 
(Adjusted HR, 3.61; 95%CI, 1.14 - 11.46; P = 0.029), and severe hyperglycemia (FPG 
≥ 11.1 mmol/L) (Adjusted HR, 11.86; 95%CI, 1.21-116.44; P=0.034). 
Conclusions: T2DM status aggravated the clinical condition of COVID-19 patients and 
increased their critical illness risk. Poor fasting blood glucose  (≥ 11.1 mmol/L) and 




 T2DM with severe SARS-CoV-2 infection had more severe inflammation, 
coagulation activation, myocardia injury, hepatic injury, and kidney injury. T2DM 
aggravated the clinical status of COVID-19, increased their critical illness rate and 
mortality.  
 Glucocorticoid treatment and poor fasting blood glucose (≥11.1mmol/L) control 
were found risk factors of fatality in T2DM patients with severe COVID-19.  
Keywords: corona virus disease 2019 (COVID-19), type 2 diabetes, glucocorticoid, 
anti-hyperglycaemic drugs, clinical status. 




The pandemic of COVID-19 has now infected over 9 million people worldwide.1 It has 
had a catastrophic impact on human lives, particularly the elderly and those with 
comorbidities.2, 3 People with type 2 diabetes (T2DM) appear to have a higher risk for 
SARS-CoV-2 infection with a prevalence of 5-20%,2-7 because they are generally older 
and often have other comorbidities. Previous studies have also shown that diabetes is 
a risk factor for severe cases of viral infections, including SARS, MERS, and H1N1.8-
11 Moreover, most diabetes patients with COVID-19 end up with a severe form of the 
disease.3 In a series of 174 inpatients with COVID-19, 24 of whom had diabetes, there 
was a rapid progression of the chest infection necessitating a chest CT scan test within 
24-48h,12 a worse prognosis and higher risk/percentage to develop composite 
endpoints,3 in the diabetes patients. More importantly, diabetes patients appear to 
have a higher fatality rate.3, 13 
Patients with diabetes may be susceptible to more severe SARS-CoV-2 infection due 
to immune system dysfunction.14 Viral infections could also induce a diabetes state, or 
worsen hyperglycemia in people with diabetes, which may adversely influence 
prognosis.15-18 Moreover, glucocorticoid use may further aggravate the situation. Anti-
hyperglycaemic treatments may be limited because some oral drugs (i.e. metformin) 
are potentially harmful to COVID-19 patients with hypoxia. In this observational study, 
we characterized risk factors for severe COVID-19 with and without T2DM, and 
described the effects of commonly prescribed anti-hyperglycaemic drugs, and 
glucocorticoid therapy on clinical outcomes in hospitalized T2DM patients with severe 
COVID-19, which still remain unanswered. 19-22 
 
Methods 
Study design and participants 
The diagnosis and clinical classification (mild, moderate, severe, and critical) of 
COVID-19 patients were carried out by two independent doctors based on the 
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Guideline of Novel Coronavirus Pneumonia (7th Edition) issued by the Chinese 
National Health Commission.23 Real-time reverse transcription polymerase chain 
reaction (RT-PCR) assay for SARS-CoV-2 was performed based on the 
recommendation by the National Institute for Viral Disease Control and Prevention 
(China).24 All enrolled patients were confirmed COVID-19 cases with RT-PCR and 
admitted to Renmin Hospital of Wuhan University from January 30, 2020, when the 
first COVID-19 patient was admitted, to April 26, 2020, when the last COVID-19 patient 
was discharged. The clinical outcomes (cured or died) and laboratory parameters on 
admission and endpoint were recorded. This case series study was approved by the 
institutional ethics board of Renmin Hospital of Wuhan University (NO. WDRY2020-
K081). Written, informed consent was waived in light of the urgent need to collect the 
data for this study. 
Data collection 
The Chinese guideline classified the patients into five categories: asymptomatic 
(positive virology test without symptoms), mild (symptoms), moderate (CT scan test 
for viral pneumonia), severe (oxygen saturation ≤93% or oxygenation index < 300), 
critical (require ICU admission or invasive oxygen treatment).23   
We encountered many difficulties in justifying to request some tests during the 
outbreak of COVID-19. Oral glucose tolerance test (OGTT) to diagnose T2DM and 
HbA1c were not routinely requested since they were considered low priorities for 
COVID-19 patients, making the diagnosis of new onset T2DM screening impossible. 
We have therefore included patients with known T2DM history for the Diabetes group 
excluding patients with elevated glucose (Fasting Blood Glucose ≥ 6.1mmol/L or 
random glucose ≥ 11.1mmol/L) from non-diabetic group to make the analysis more 
coherent. 
Epidemiological, clinical characteristics, laboratory parameters, clinical status and 
outcomes were obtained from the electronic medical records of Renmin Hospital of 
Wuhan University. The data were entered and cross-reviewed by at least two 
independent team members. Information recorded included demographic data, 
medical history, underlying comorbidities, symptoms, signs, laboratory findings (e.g., 
random blood glucose on admission, cellular immunity, metabolic enzymes and other 
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biochemical parameters), treatment measures (e.g., oxygen therapy, ventilator use), 
and drugs (e.g., insulin, anti-hyperglycaemic agents and glucocorticoids use). Fasting 
plasma glucose (FPG) was measured for all patients during hospitalization. 
Comorbidities, including diabetes, cerebral diseases, cardiovascular diseases, 
chronic renal diseases, digestive diseases, pulmonary diseases and surgical 
history, were defined as documented history in the admission notes. Cerebral diseases 
refer to cerebral infarction, epilepsy, Alzheimer's disease, and Parkinson's disease. 
Cardiovascular diseases refer to hypertension, coronary heart disease, arrhythmia, 
cardiomyopathy and heart failure. Chronic renal diseases refer to chronic renal 
insufficiency, chronic renal failure, chronic nephritis and nephrotic syndrome. Digestive 
diseases refer to gastritis, gastric and duodenal ulcer, enteritis, cholecystitis and 
pancreatitis. Pulmonary diseases refer to asthma, chronic bronchitis, emphysema, 
chronic obstructive pulmonary disease, tuberculosis, pulmonary embolism, and 
interstitial pneumonia. Surgical history refers to major abdominal, brain surgery and 
cardiothoracic surgery including cardiac bypass, lung surgery etc.  
Clinical Status Evaluation. Five-category ordinal scale of clinical status was used for 
ventilation status evaluation which ranged from 1-5 including 25: 1-not requiring 
supplemental oxygen; 2-requiring low-flow oxygen therapy; 3-requiring high-flow nasal 
cannula oxygen therapy (HFNC); 4-requiring noninvasive mechanical ventilation (NIV); 
5-requiring extracorporeal membrane oxygenation (ECMO)/invasive mechanical 
ventilation (IMV). National Early Warning Score 2 (NEWS2) is an aggregated weighted 
score of 0–20, based on measurements of heart rate, systolic blood pressure, arterial 
oxygen saturation, respiratory rate, level of consciousness, temperature and 
supplemental oxygen.26 
Statistical analysis 
Categorical variables were described as frequency and percentages (%), and 
continuous variables were described with median and interquartile range (IQR) values. 
Means for continuous variables were compared using independent group t tests when 
the data were normally distributed; otherwise, the Mann-Whitney test was used. 
Proportions for categorical variables were compared using Fisher’s exact test or the χ2 
test. Logistic regression analysis was used to analyze independent risk factors for 
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mortality of COVID-19 patients. The risk for composite endpoints and corresponding 
hazard ratio (HR) were analyzed using Cox proportional hazard model. The cumulative 
rates of death were plotted by applying Kaplan-Meier method. All statistical analyses 
were performed using SPSS 22.0 (IBM Software) and Graphpad Prism 8 (Graphpad), 
and p <0.05 was considered statistically significant. 
Results 
Study sample  
From January 30, 2020 to April 26, 2020, 1584 patients diagnosed with COVID-19 
were admitted to Renmin Hospital of Wuhan University, 1093 of whom in the first 
month, from January 30 to February 29, 2020. After excluding patients with pregnancy 
(n = 30), and those transferred to other facilities (n = 243), 274 mild/moderate cases 
and 546 severe/critical cases were included in the study sample. Patients with fasting 
glucose ≥6.1mmol/L or random glucose ≥11.1mmol/L in those without a previous 
diagnosis of T2DM (n = 182) were excluded. This left 114 patients with T2DM history 
and 250 patients without T2DM history (Figure 1). 
Presenting characteristics 
Of the 364 confirmed severe/critical COVID-19 patients, 305 (83.8%) cases were 
discharged, and 59 (16.2%) died. 66.5% (242) had one or more coexisting co-morbid 
medical conditions. The five most common coexisting conditions were: cardiovascular 
diseases (42.3% (n=154)), DM (31.3% (n=114)), surgical history (12.4% (n=45)), 
pulmonary disease (10.7% (n=39)), and digestive disease (10.2% (n=37)). The 
patients aged 60–69 years had the highest percentage (31.0%(n=113)) of COVID-19 
compared to other age groups. Fatality rate increased with increasing age (Figure 2A). 
There was a higher fatality rate [(27(23.7%) vs. 32(12.7%); P = 0.014]; and older age 
[Median (IQR), 66(57-73) vs. 64(52-73); P = 0.044] in T2DM patients compared with 
non-DM patients (Table 1). Days from symptom onset to admission or gender did not 
differ between T2DM and non-DM patients (Table 1). 
In multiple logistic regression analysis for fatality cohorts including age, gender, and 
co-morbidities (diabetes, cerebral diseases, cardiovascular diseases, chronic renal 
diseases, digestive disease, pulmonary disease, and surgical history), age (OR, 1.04; 
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95% CI, 1.02 - 1.07; P < 0.001), T2DM (OR, 1.81; 95% CI, 1.06 - 3.07; P = 0.029), and 
surgical history (OR, 2.37; 95% CI, 1.20 - 4.71; P = 0.014) were found to be risk factors 
for fatality of severe/critical inpatients with COVID-19. 
Laboratory parameters in COVID-19 patients with and without diabetes 
There were several differences in laboratory findings between T2DM and non-DM 
patients, including lower levels of serum albumin and estimated glomerular filtration 
rate (eGFR), as well as higher levels of white blood cells (WBC), C-reactive protein 
(CRP), IL-6, aspartate aminotransferase (AST), lactate dehydrogenase (LDH), NT-
proBNP, creatine kinase isoenzyme-MB (CK-MB), myoglobin, cardiac troponin I (cTnI), 
and D-dimer in T2DM (P < 0.05 or P < 0.001). The levels of lymphocyte (LYM), alanine 
aminotransferase (ALT), creatinine (Cr), creatine kinase (CK),  lactic acid (LA), and 
cellular immune (CD3+, CD4+, CD8+, CD19+, and CD16+56 + cell counts, and 
CD4+/CD8+) did not differ between T2DM and non-DM (Table 1). Taken together, our 
results suggest that T2DM patients with COVID-19 had more severe inflammation, 
coagulation activation, myocardia injury, hepatic injury, and kidney injury. 
The impact of T2DM status on the prognosis of COVID-19 patients 
On admission, NEWS2 score of T2DM patients was higher than non-DM patients 
(Median (IQR), 5(4-8) vs. 5(3-6); P = 0.018) (Figure 2C). It indicated that T2DM 
patients were more severely ill than non-DM patients on admission. During 
hospitalization, their ventilation therapy was defined as five-category ordinal scale of 
clinical status, the score in T2DM was higher than non-DM (Median (IQR): 3(2-3) vs. 
2(2-3); P < 0.001) (Figure 2D). More T2DM patients required IMV/ECMO therapy than 
non-DM patients (15(13.2%) vs. 8(3.2%); P < 0.001). After adjusting for age, gender, 
comorbidities, and NEWS2 on admission, the survival rate of T2DM (Adjusted HR, 
1.77; 95%CI, 1.02 - 3.05; P = 0.041) was lower than non-DM patients with COVID-19 
(Figure 2B). 
Glucocorticoid therapy and the prognosis of COVID-19 patients with T2DM 
In this study, 74(64.9%) of T2DM patients and 134(53.6%) of non-DM patients had 
glucocorticoid (GC) therapy (dose from 20mg/day to 160 mg/day, duration range of 1-
28 days). Admission NEWS2 scores didn’t differ significantly between GC and no GC 
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treatment in both T2DM and non-DM patients (P > 0.05; Figure 3D). After adjusting for 
age, gender, comorbidities, and NEWS2 on admission, the results significantly 
demonstrated a lower overall survival rate in the patients treated with GC compared 
with no GC treatment (Adjusted HR, 3.61; 95%CI, 1.14 - 11.46; P = 0.029) (Figure 3A). 
This contrasted with non-DM patients in whom GC treatment was not risk factor for 
fatality (Adjusted HR, 1.41; 95%CI, 0.67 - 2.96; P = 0.362) (Figure 3B). The fatality for 
DM patients treated with GC was 31.1%, which was about 3 times than that with no 
GC treatment in both T2DM (10.0%, P=0.012) and non-DM patients (10.3%, P<0.001), 
and about twice than that with GC treatment in non-DM patients (14.9%, P=0.007) 
(Figure 3C). During hospitalization, more patients treated with GC required invasive 
ventilation than patients without GC treatment both in T2DM and non-DM patients (P 
< 0.001; Figure 3E). The level of IL-6, a marker of inflammation, increased significantly 
after GC treatment in T2DM patients (P = 0.049), but not in non-DM patients (P = 0.36) 
(Figure 3F). 
Anti-hyperglycaemic drugs use and prognosis of diabetes patients with COVID-
19 
Among the 114 T2DM patients, 83.3% (n=95) with treated with one or more anti-
hyperglycaemic drugs including: basal insulin (24.6%(n=28)), premixed 
insulin(14.0%(n=16)), Aspart/Lispro/Human insulin (42.1%(n=48)), acarbose 
(46.5%(n=53)), metformin (26.3%(n=30)), sulfonylureas (14.9%(n=17)), dipeptidyl 
peptidase-4 inhibitors (DDP4i) (6.1%(n=7)), and sodium-glucose co-transporter-2 
inhibitors (SGLT2i) (0.9%(n=1)). All these drugs were prescribed the conventional 
dosages according to their instructions. 16.7% (n=19) of T2DM patients didn’t use any 
anti-hyperglycaemic drugs and were on diet treatment alone. The fatality rates of 
patients treated with basal insulin (14.3%, P = 0.045), premix insulin (6.3%, P = 0.022), 
metformin (6.7%, P = 0.008), acarbose (7.5%, P = 0.002), sulfonylureas (5.9%, P = 
0.02), insulin (including basal insulin, premixed insulin, and Aspart/Lispro/Human 
insulin) and oral anti-hyperglycemic drugs (OAHs, including acarbose, metformin, 
sulfonylureas, DDP4i, and SGLT2i, 7.3%, P = 0.003), and OAHs alone (7.4%, P = 
0.009) were lower than that of diet alone treated T2DM patients (42.1%)(Table 2). 
NEWS2 scores on admission didn’t differ among these patients (P > 0.05). Patients 
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treated with DDP4i or OAHs alone had lower ventilation score than that with diet 
treatment alone (P < 0.05). Premix insulin, acarbose, metformin, DDP4i, insulin and 
OAHs, and OAHs alone improved fasting blood glucose metabolism (P < 0.05 or P < 
0.001) (Table 2).  
The average fasting plasma glucose (FPG) was analyzed, and divided into three 
groups including: euglycemia (3.9-6.0 mmol/L), moderate hyperglycaemia (6.1-11.0 
mmol/L), and severe hyperglycaemia (≥11.1 mmol/L). No hypoglycemia readings 
(<3.9 mmol/L) were recorded. By applying mixed-effect Cox model adjusting for age, 
gender, comorbidities, NEWS2 on admission, GC treatment, and anti-hyperglycaemia 
treatment, compared with euglycemia, severe hyperglycaemia (Adjusted HR1, 11.86; 
95%CI, 1.21-116.44; P=0.034) showed higher risk of all-cause fatality in T2DM 
patients; however, moderate hyperglycaemia (Adjusted HR2, 4.51; 95%CI, 0.40-51.30; 
P=0.225) showed no difference (Figure 4).  
 
Discussion 
Diabetes has been suggested that confers worse prognosis on COVID-19.3,13 However, 
the impact of T2DM and its management, especially fast glucose control on the 
prognosis of patients with COVID-19 have not been fully evaluated. Until now, no 
specific treatment has been validated for its effectiveness, and no antiviral agent has 
been found to provide benefit in reducing mortality of COVID-19 patients, except for 
oxygen therapy or early hospitalization.25 In this observational study, we described that 
SARS-CoV-2 infection in T2DM was associated with more severe inflammation, 
coagulation activation, myocardia injury, hepatic injury, and kidney injury. T2DM 
aggravated the clinical status of COVID-19, increased their critical illness rate and 
mortality. GC treatment and fasting blood glucose ≥11.1 mmol/L were found risk 
factors of fatality in these patients.  
The prevalence of diabetes or the comorbidities of diabetes in COVID-19 is from 5-
20%.2-7 During the early outbreak, hospitalized patients consisted of severe cases 
older patients amongst whom diabetes patients were well represented. However, later 
on, more mild cases were hospitalized due to expansion of medical services for 
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COVID-19 patients, and the proportion of diabetes patients started to reflect that of the 
general population. The most recent survey showed that the overall prevalence of 
diabetes in China is 12.8% with only half (6%) having a history of diabetes (self-
reported diabetes).27 The overall prevalence of diabetes in those aged ≥40 years was 
15.6%.5 Our data shows that the prevalence history of diabetes in patients with severe 
COVID-19 is 31.3%, strongly suggesting that diabetes is a risk factor for more severe 
COVID-19. 
Our study also shows that a history of T2DM is a risk factor for the progression and 
prognosis of COVID-19,12 with a higher risk of severe pneumonia and higher chest CT 
scores. It also showed that T2DM patients had more severe organ impairments and 
worse inflammation. Moreover, diabetes patients have worse glycaemic control which 
requires more anti-hyperglycaemic treatment following COVID-19 or hospitalization. 
Wu et al.28 reported that diabetes was a risk factor of developing ARDS in COVID-19. 
All of these indicate that diabetes status is a major risk factor for worse clinical 
outcomes/fatality in COVID-19 patients. Indeed, based on our analysis of patients’ 
clinical status, the survival curve showed that the prognosis for T2DM patients was 
worse. NEWS2 analysis on admission demonstrated that patients with a history of 
T2DM were generally sicker on admission and older which might be the explanation 
for the lower survival rate. The time of symptom onset to admission showed no 
difference between T2DM vs. non-DM patients. However, it has been reported that the 
SARS-CoV-2 infection was more likely to affect older men with diabetes.6 As is widely 
reported, age is a strong indicator for COVID-19 prognosis. Further logistic regression 
analysis showed that T2DM is an independent risk factor for severe status and fatality 
of COVID-19 patients. Our data also shows that SARS-CoV-2 infection affects men 
and women equally, and also indicates that gender may not be a risk factor for a poor 
outcome, in keeping with recent reports from China.4,13 
Huang et al.2 reported that SARS-CoV-2 infection in Wuhan caused multiple organ 
dysfunction and death in severe COVID-19 patients. In our study, laboratory 
parameters associated with multiple organ function were tested on admission. The 
results showed abnormal or worse albumin, eGFR, WBC, CRP, IL-6, AST, LDH, NT-
proBNP, CK-MB, myoglobin, cTnI, and D-dimer in COVID-19 patients with T2DM. 
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These data indicate that SARS-CoV-2 infection in T2DM is associated with more 
severe inflammation, coagulation activation, myocardia injury, hepatic injury, and 
kidney injury. Therefore, diabetes patients are more likely to develop multiple organ 
failures and die as a result.4 ACE2, the SARS-CoV-2 receptor, is present in endothelial 
and smooth muscle cells in multiple organs,29 suggesting that SARS-CoV-2 infection 
may induce multiple organ injury, possibly via ACE2. It is well recognized that viral 
infections can worsen blood glucose control. It has also been found that ACE2 protein 
shows strong immunostaining in islets, suggesting that SARS-CoV-2 may contribute 
to the development of diabetes or exacerbation of hyperglycaemia by damaging 
pancreatic islets via ACE2.30 Moreover, high levels of inflammatory cytokines such as 
IL-6 and TNF-a in diabetes patients and animal models suggests that diabetes may 
significantly promote the production of TLR4-induced IL-6 increase.12,31 IL-6-dominated 
cytokine storms have been identified as one of the leading causes of death from 
pneumonia caused by SARS-CoV-2 infection.32, 33 
During the current pandemic of COVID-19, systemic GC was used for their potent anti-
inflammatory properties.34 The use of GC requires a knowledge of the related side 
effects (e.g. avascular necrosis, psychosis, diabetes), their adequate prevention and 
a prompt treatment if necessary. A randomized, controlled clinical trial in a preprint 
posted to medRxiv has found that dexamethasone with mechanic ventilation was 
shown to reduce deaths from severe COVID-19. 35 However, whether GC should be 
used for the treatment of lung injury related to SARS-CoV-2 infection is still 
debatable.36 In the past, steroid administration did not clearly improve the mortality rate 
of patients affected by SARS-CoV and MERS-CoV.36 Our study found that a higher risk 
of all-cause fatality with GC treatment in severe COVID-19 patients with T2DM. 
Although GC was more likely to be used in critical cases, our data indicated that GC 
treatment may be potentially harmful to T2DM patients with critical COVID-19 if not 
properly used. Firstly, the fatality in DM patients treated with GC was about twice than 
that in non-DM patients with GC treatment. Secondly, GC treatment was associated 
with an increased IL-6 levels in T2DM, but not in non-DM patients. It suggested that 
we need to further define the indications for GC treatment and use it on the right 
patients. 
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The anti-hyperglycaemic treatment approach for T2DM patients with COVID-19 is 
uncertain because some oral drugs have not been recommended.19-22 It seems that 
insulin may be the safest choice during this uncertainty. We analyzed the influences of 
anti-hyperglycemic drugs on the prognosis of COVID-19 with T2DM. There were three 
types of insulin with Aspart/Lispro/Human insulin the most widely used, and four types 
of oral anti-hyperglycemic drugs with acarbose the most commonly used. Of these 
anti-hyperglycemic drugs, basal insulin, premix insulin, metformin, acarbose, 
sulfonylureas, insulin and OAHs, and OAHs alone showed lower fatality than diet 
treatment alone, despite their similar NEWS2 or clinical status on admission/at 
baseline. It seems to be consistent with their effects on improving fasting blood glucose 
metabolism. A recent study reported that a “good blood glucose control (3.9-10moml/L)” 
was associated with less fatality.37 Our study indicated similarly but more precisely, we 
recommended to aim fast blood glucose at (3.9-11.0 mmol/L) for better survival. 
We have excluded patients with elevated glucose (FPG ≥ 6.1mmol/L or random 
glucose ≥ 11.1mmol/L) from non-diabetic group in our analysis. However, they showed 
same results as pre-existing diabetes patients for those with GC treatment or FPG 
≥11.1 mmol/L (Supplementary Table). Moreover, elevated glucose was found in 182 
patients (59 without GC treatment), indicating there is undiagnosed diabetes in these 
patients.  
In summary, a history of T2DM aggravated the clinical status of COVID-19 patients, 
increased their critical illness and mortality rates. SARS-CoV-2 infection in diabetes 
led to more severe inflammation, coagulation activation, myocardia injury, hepatic 
injury, and kidney injury. GC treatment and fasting plasma glucose ≥11.1 mmol/L were 
found to be risk factors for fatality in diabetes patients with COVID-19. There are some 
limitations of this study that took place within the context of an emergency outbreak 
including: lack of a control group- either as a matched control to compare patient 
groups or randomized control for the assessment of treatments. Besides, our study is 
based on small numbers of diabetic patients. However, our study provided evidence 
for informing clinical decisions. 
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Tables and Figures 
Characteristics DM (n=114) non-DM (n=250) Total (n=364) P 
Age, years 66(57-73) 64(52-73) 65(55-73) 0.044 
Gender - Men 62 (54.4%) 144 (57.6%) 206 (56.6%) 0.571 
Days onset to Ad 10(7-14) 10(7-14) 10(7-14) 0.568 
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Died cases 27(23.7%) 32(12.7%) 59(16.2%) 0.014 
Laboratory 
Parameters/Ad 
        
WBC(×109/L) 6.77(5.30-8.61) 5.27(3.99-7.28) 5.64(4.26-7.86) <0.001 
LYM(×109/L) 0.87(0.55-1.27) 1.0(0.75-1.41) 0.97(0.71-1.38) 0.134 
CRP(mg/L) 56.6(17.2-111.9) 28.6(6.6-70.5) 37.8(9.4-81.3) <0.001 
IL-6(pg/mL) 17.34(6.59-38.39) 6.56(3.34-23.13) 8.99(4.28-28.81) 0.009 
ALT(U/L) 24.5(17.8-57.0) 23.0(16.0-36.0) 24.0(16.0-40.0) 0.873 
AST(U/L) 28.5(20.0-47.3) 28.0(20.0-40.0) 28.0(20.0-41.0) 0.032 
ALB(g/L) 34.5(31.8-37.4) 36.0(32.8-39.3) 35.5(32.4-38.6) 0.012 
Cr(μmol/L) 65.0(52.0-74.8) 64.0(51.0-76.5) 64.0(51.0-76.0) 0.729 
eGFR(mL/min·1.73m2) 94.4(74.0-101.8) 94.2(85.1-106.0) 94.3(83.1-104.6) 0.007 
LDH(U/L) 326(238-449) 281(216-360) 295(222-377) <0.001 
NT-proBNP(pg/mL) 289.8(133.1-986.0) 122.4(46.3-429.4) 171.2(56.1-544.8) 0.014 
CK(U/L) 55(36-119) 63(40-111) 61(38-113) 0.835 
CK-MB(ng/mL) 1.31(0.85-2.62) 1.05(0.66-1.59) 1.14(0.70-1.90) <0.001 
Myoglobin(μg/L) 60.59(34.13-122.80) 45.59(29.38-82.35) 49.99(31.46-92.01) 0.008 
cTnI(ng/mL) 0.008(0.005-0.029) 0.005(0.005-0.018) 0.005(0.005-0.022) <0.001 
D-dimer(mg/L) 1.31(0.62-5.79) 0.89(0.42-3.31) 1.03(0.49-3.91) 0.02 
LA(mmol/L) 2.1(1.7-2.9) 2.0(1.6-2.8) 2.1(1.6-2.9) 0.488 
CD3(/µl) 505(284-850) 604(399-847) 561(364-846) 0.131 
CD4(/µl) 321(167-491) 380(239-531) 357(217-514) 0.215 
CD8(/µl) 136(75-289) 209(129-327) 194(110-305) 0.147 
CD4/CD8 1.94(1.34-3.16) 1.77(1.23-2.69) 1.83(1.24-2.78) 0.109 
CD19(/µl) 136(80-192) 127(76-196) 129(77-193) 0.5 
CD16+56(/µl) 111(55-191) 116(75-188) 112(70-190) 0.755 
 
Table 1: Demographic, laboratory indices and clinical course and outcomes of 
diabetes (DM) vs. non-diabetes (non-DM) patients with COVID-19. 
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Data was shown with median (interquartile range, IQR) and No. of patients (%). 
P <0.05 for DM vs. non-DM was considered statistically significant. Abbreviations: DM, 
diabetes; WBC, white blood cells; LYM, lymphocyte; CRP, C-reactive protein; ALT, 
alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; Cr, 
creatinine; eGFR, estimated glomerular filtration rate; CK, creatine kinase; LDH, 
lactate dehydrogenase; CK-MB, creatine kinase isoenzyme-MB; cTnI, cardiac troponin 
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 admission endpoint **P  
Insulin alone 14(51.9%) 27 6.0(4.0-8.0) 3.0(2.0-5.0)  9.22(6.49-15.42) 9.20(5.74-12.89) 0.822 
OAHs alone 2(7.4%)* 27 5.0(4.0-7.0) 2.0(2.0-3.0) * 9.17(6.59-10.39) 6.23(5.51-8.35) 0.015 
Insulin + OAHs 3(7.3%)* 41 5.0(3.0-7.0) 2.0(2.0-3.0)  11.05(7.39-16.77) 6.83(5.80-9.16) <0.001 
Insulin        
Basal 4(14.3%)* 28 5.0(4.0-7.8) 3.0(2.0-3.0)  12.45(8.79-19.99) 7.41(5.80-10.14) 0.145 
Premix 1(6.3%)* 16 5.0(4.3-8.0) 2.5(2.0-3.0)  12.70(8.57-18.26) 6.47(5.39-9.60) 0.002 
Aspart/Lispro/Human 16(33.3%) 48 5.0(4.0-8.0) 3.0(2.0-4.0)  11.20(7.14-15.97) 8.28(5.80-10.95) 0.144 
OAHs               
Metformin 2(6.7%)* 30 4.0(3.0-6.0) 2.0(2.0-3.0)  9.86(6.82-13.86) 6.36(5.87-8.36) 0.021 
Acarbose 4(7.5%)* 53 5.0(4.0-8.0) 2.0(2.0-3.0)  10.15(7.17-14.79) 6.83(5.56-9.16) <0.001 
Sulfonylureas 1(5.9%)* 17 4.0(2.5-7.0) 2.0(2.0-3.0)  7.59(5.33-9.95) 5.80(4.91-8.51) 0.134 
DDP4i 0(0) 7 6.0(5.0-8.0) 2.0(2.0-2.0) * 10.28(7.13-11.93) 6.10(4.92-9.20) 0.028 
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SGLT2i 0(0) 1 9.0 3.0 17.22 6.3 / 
Diet treatment alone 8(42.1%) 19 6.0(4.0-8.0) 3.0(2.0-4.0)  9.53(6.84-15.21) 6.07(5.84-9.60) 0.595 
 
Table 2: Anti-hyperglycaemic drugs use and prognosis of type 2 diabetes patients with COVID-19. 
Data was shown as numbers (percentages, %), and median (interquartile range, IQR). *P<0.05 vs. diet treatment alone; **P, FPG on admission 
vs. FPG at endpoint.  Abbreviations: OAHs, oral anti-hyperglycaemic drugs; NEWS2, National Early Warning Score 2; FPG, fasting plasma 
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Characteristics Excluded cases (n=182) 
Age, years 65(56-74) 
Gender - Men 100 (54.9%) 
Days from onset to admission 10(7-14) 
Died cases 52(28.6%) 
FPG (mmol/L) n (mortality) 
6.1 ~ <7.0 77(20.8%) 
7.0 ~ <11.1 92(32.6%) 
≥11.1 13(46.2%) 
GC treatment 123(35.0%) 
No GC treatment 59(15.3%) 
 
Supplementary Table: Demographic, fasting plasma glucose (FPG) and GC 
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Fig. 1: Flow diagram showing enrollment of COVID-19 inpatients and the 
recruitment of severe/critical cases with and without a history of type 2 
diabetes. 
 
Fig. 2: The effects of type 2 diabetes and age on the prognosis of patients with 
COVID-19 
A)The effects of type 2 diabetes (DM) vs. non-diabetes (non-DM) on the mortality of 
COVID-19 patients with severe/critical infection in the different age groups; B) The 
overall survival rate of DM vs. non-DM; C) The NEWS2 on admission of DM vs. non-
DM and D) The ventilation therapy score of DM vs. non-DM. p<0.05 is considered as 
significant and its value is as indicated in the graph. 
 
Fig. 3 The effects of glucocorticoid (GC) therapy on the prognosis of type 2 
diabetes (DM) and non-diabetes (non-DM) patients with severe/critical COVID-19.   
A)The overall survival rate of GC therapy in DM patients; B) The overall survival rate 
of GC therapy on non-DM patients; C) The fatality of GC treatment (+) vs. no GC 
treatment (-) in DM (+) and non-DM (-) patients; D) The NEWS2 of GC treatment (+) 
vs. no GC treatment (-) in DM (+) and non-DM (-) patients; E) Ventilation therapy scores 
of GC treatment (+) vs. no GC treatment (-) in DM (+) and non-DM (-) patients; F) The 
effects of GC on IL-6. p<0.05 is considered as significant and its value is as indicated 
in the graph.  
 
Fig. 4 The overall survival rates of average fasting plasma glucose (FPG) 
p<0.05 is considered as significant and its value is as indicated in the graph. 
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Fig. 4 The overall survival rates of average fasting plasma glucose (FPG) 
p<0.05 is considered as significant and its value is as indicated in the graph. 
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